Cell reprogramming therapy for Parkinson's disease
Wenjing Dong1,2, Shuyi Liu1,2, Shangang Li1,2
1State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, Yunnan Province, China.
Neural Regeneration Research
|March 25, 2024
Summary
Cell reprogramming offers a promising new avenue for Parkinson's disease treatment by regenerating lost neurons. Strategies like induced pluripotent stem cells and direct reprogramming show potential, addressing limitations of earlier therapies.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Stem Cell Biology
Background:
- Parkinson's disease involves progressive loss of dopaminergic neurons.
- Previous cell replacement therapies faced ethical concerns and tumor risks.
- New strategies aim to overcome these limitations for effective Parkinson's treatment.
Purpose of the Study:
- To review the current status of cell reprogramming for Parkinson's disease.
- To focus on induced pluripotent stem cells (iPSCs) and direct reprogramming techniques.
- To discuss preclinical and clinical advancements and associated challenges.
Main Methods:
- Review of existing literature on cell reprogramming in Parkinson's disease models.
- Analysis of induced pluripotent stem cell (iPSC) therapy, including preclinical and clinical data.
- Examination of direct reprogramming of fibroblasts and astrocytes into neurons.
- Discussion of in vivo reprogramming controversies.
Main Results:
- Both iPSCs and direct reprogramming show promise for Parkinson's disease treatment.
- iPSC therapy has advanced through preclinical animal models and early clinical research.
- Direct reprogramming offers a potential alternative, bypassing ethical and safety concerns.
- Ongoing research addresses ethical considerations and tumor formation risks.
Conclusions:
- Cell reprogramming strategies, including iPSCs and direct reprogramming, represent a significant advancement in Parkinson's disease therapy.
- These methods offer potential solutions to overcome limitations of traditional cell replacement therapies.
- Further research and clinical trials are necessary to fully establish the safety and efficacy of cell reprogramming for Parkinson's disease.
More Related Videos
09:44Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
153
11:42In vitro Modeling for Neurological Diseases using Direct Conversion from Fibroblasts to Neuronal Progenitor Cells and Differentiation into Astrocytes
Published on: June 10, 2021
4.9K
Related Concept Videos
01:24Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
01:21EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
01:15Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
01:29Somatic to iPS Cell Reprogramming
2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
01:22iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
01:24Methods of Nuclear Reprogramming
1.8K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
1.8K